Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | APEX1 | P27695 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97551 | 0.91 | MAPK1 (0.70) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL30530511 | 0.91 | MAPK1 (0.70) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL11138401 | 0.88 | MAPK1 (0.63) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL11137643 | 0.87 | MAPK1 (0.61) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL11096941 | 0.86 | MEN1 (0.61) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL27780501 | 0.83 | MAPK1 (0.61) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL2255490 | 0.83 | MEN1 (0.62) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL2308197 | 0.82 | MEN1 (0.56) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL763166 | 0.81 | LMNA (0.64) | HPGDALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL8248960 | 0.81 | LMNA (0.64) | HPGDALDH1A1LMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951228-B1 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1954268-B1 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| EP-1954268-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951228-A2 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007061695-A2 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | HPGD 551/4885ALDH1A1 606/4885KDM4E 4469/4885 |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | HPGD 351/4885ALDH1A1 647/4885KDM4E 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.